2 Result: Argenx
Medical Breakthroughs: argenx's VYVGART Hytrulo and Pfizer's TALZENNA Garner FDA Approval
June 21st, 2023
argenx SE (Nasdaq: ARGX) has received approval from the U.S. Food and Drug Administration (FDA) for VYVGART Hytrulo, a subcutaneous injection used to treat generalized myasthenia gravis (gMG) in adult patients who test positive for anti-acetylcholine. Read more
Akebia Therapeutics, MDxHealth, Avis Budget, argenx, Five9, Inventiva: Analyst Upgrades and Initiations Point to Potential Upsides
May 31st, 2023
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company, received an upgrade from Neutral to Overweight by Piper Sandler, with the price target raised from $2 to $4. On Wednesday, $AKBA closed at $1.04, indicating a potential u. Read more
Want To Find Some News?
News By Industries
Recent Post
-
October 29th, 2026
Treasury Sanctions Facilitators of DPRK IT Worker Fraud Targeting U.S. Businesses
October 28th, 2026Treasury Sanctions Rwandan Ministry of Defence and Financial Institution Supporting M23
October 28th, 2026October 26th, 2026FAA Releases Draft Design Standards for Vertical Flight Facilities
October 22nd, 2026
Member Login